MARLBOROUGH, Mass.,
Nov. 7, 2018 /PRNewswire/ -- RXi
Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company
developing the next generation of immuno-oncology therapeutics
based on its proprietary self-delivering RNAi (sd-rxRNA®)
therapeutic platform, will present a poster highlighting data
demonstrating the potential of sd-rxRNA to improve NK cell potency
in adoptive cell transfer (ACT) at SITC 2018, the 33rd Annual
Meeting & Pre-Conference Programs of the Society for
Immunotherapy of Cancer (SITC).
Logo -
http://mma.prnewswire.com/media/594748/RXi_Pharmaceuticals_Corporation_Logo.jpg
The poster, titled "sd-rxRNA to Enhance NK Cell Activity for
Adoptive Cell Transfer" (Poster #P258), will be available for
viewing from 12:20–1:50 p.m. ET and 7:00–8:30 p.m. ET on
Saturday, November 10, 2018.
The poster will also be available under the "Investors – Events
and Presentations" section of the Company's website,
http://www.rxipharma.com/, approximately one hour following the
presentation.
SITC 2018 is being held November 7-11,
2018 at the Walter E. Washington Convention Center in
Washington, DC.
About RXi Pharmaceuticals
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a
biotechnology company developing the next generation of
immuno-oncology therapeutics based on its self-delivering RNAi
(sd-rxRNA®) therapeutic platform. The Company's discovery and
research efforts are focused on developing sd-rxRNA therapeutic
compounds to be used in the context of adoptive cell transfer by
targeting checkpoints or other gene targets, or to be used as
intratumoral immunotherapy. We aim to maximize the power of our
sd-rxRNA therapeutic compounds by weaponizing therapeutic immune
effector cells to attack cancer, and to make tumors more
susceptible to such attacks, and ultimately provide patients
battling cancers with a powerful new treatment option that goes
beyond current treatment modalities. RXi intends to develop
immuno-oncology therapeutics on our own and in collaboration with
partners. For additional information, visit the Company's
website, http://www.rxipharma.com/.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements are neither historical facts nor
assurances of future performance. These statements are based only
on our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, projections,
anticipated events and trends, the economy and other future
conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict and many of
which are outside of our control. Our actual results may
differ materially from those indicated in the forward-looking
statements as a result of a number of important factors, including,
but not limited to, the safety and efficacy of our product
candidates, future success of our clinical trials and scientific
studies, our ability to enter into strategic partnerships and the
future success of these strategic partnerships, the availability of
funds and resources to pursue our research and development projects
and general economic conditions. Our Annual Report on
Form 10-K and subsequent Quarterly Reports on Form 10-Q
include detailed risks under the caption "Risk Factors" that may
affect our business, results of operations and financial condition.
Readers are urged to review these risk factors and to not act in
reliance on any forward-looking statements, as actual results may
differ from those contemplated by our forward-looking statements.
RXi does not undertake to update forward-looking statements to
reflect a change in its views, events or circumstances that occur
after the date of this release.
Contact
RXi Pharmaceuticals Corporation
ir@rxipharma.com
View original
content:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-to-present-new-data-demonstrating-the-ability-of-sd-rxrna-to-enhance-nk-cell-activity-for-adoptive-cell-transfer-at-sitc-2018-300745279.html
SOURCE RXi Pharmaceuticals Corporation